Catalent cuts 130 workers in Indiana; Merck KGaA to build in South Korea; Schott expands US footprint
21 Mar 2024
Acquisition
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more.
Catalent is reducing its headcount by 130 employees at its facility in Bloomington, IN, across current and open roles, a company spokesperson told Endpoints. This is to focus on “increasing efficiencies and reducing costs across our business,” the company added. The site is one of three facilities Novo Nordisk is set to absorb on the back of Novo Holding’s announced acquisition of Catalent.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.